Wells Fargo & Company Argenx Se Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Argenx Se stock. As of the latest transaction made, Wells Fargo & Company holds 46,212 shares of ARGX stock, worth $27.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
46,212
Previous 47,621
2.96%
Holding current value
$27.3 Million
Previous $18.7 Million
5.99%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ARGX
# of Institutions
384Shares Held
31.6MCall Options Held
338KPut Options Held
449K-
Price T Rowe Associates Inc Baltimore, MD5.6MShares$3.31 Billion0.29% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.51MShares$2.08 Billion2.39% of portfolio
-
Janus Henderson Group PLC London, X02.47MShares$1.46 Billion0.58% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.92MShares$1.14 Billion0.52% of portfolio
-
Capital World Investors Los Angeles, CA1.51MShares$894 Million0.11% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $32.7B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...